Caribou Biosciences, Inc. (CRBU)

From the record

Caribou Biosciences, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Caribou Biosciences, Inc.'s 7 filed years say what it did: revenue went from $6 million in fiscal 2019 to $11 million in fiscal 2025, up 11.6% a year; it rose in 4 of 6 years; the deepest fall was 71% from fiscal 2023 to fiscal 2024; net income was positive in 0 of 7 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Caribou Biosciences, Inc. lost about 121 cents for every dollar of shareholders' money. Leverage: it owed about 30 cents per dollar of assets, and net share issuance: its share count grew 3.4% over the year (the filed statements).

From the record

Caribou Biosciences, Inc.'s standing among 102 graded names in its industry family: revenue of $11 million in fiscal 2025 ranks in the bottom 40% by size; a net margin of -1327.4% ranks in the bottom 30%; revenue growth of -6.9% a year over the last 3 filed years ranks in the bottom 31% (its annual reports).

From the record

Caribou Biosciences, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Haurwitz, Rachel E. (President and CEO, as filed), filing under that title since 2021-07-22, 5.3 years (top 43% of its family); the 13 officers and directors filing in the last fifteen months have been on the record a median of 5.1 years (bottom 39%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 13 people in charge now (top 49%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Caribou Biosciences, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $12 million against no long-term debt tagged leaves 7% of its assets as net cash, bottom 14% of its family; cash from operations less capital spending is -1006.8% of revenue (bottom 27%); research spending of 980.7% of revenue (top 26%) (its annual report).

From the record

Caribou Biosciences, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -6.9% a year over the last three filed years against 11.6% over all 7, slowing (bottom 31% of its family); the newest year grew 11.7% (bottom 49%); research spending grew 10% a year (top 33%); capital spending grew -40.5% a year (bottom 42%) (its annual reports). Caribou Biosciences, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Caribou Biosciences, Inc.'s newest year against its own record: revenue of $11 million in fiscal 2025 came in 31.4% above the $8 million its prior three years' pace pointed to (top 35% of its family); net income of $148 million against a prior three-year average of $117 million (bottom 27%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 15%) (its annual reports).